チサンゲレクロイセル チサンゲレクロイセル チサンゲレクれぅろぅぅ...(覚えられない) https://t.co/qDbTQFL1uV
Tisagenlecleucelとか読むこともできないので、CTL019でいいかな。。。 /Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/EgF9IJHUvH
RT @jlsteeg_doc: Novartis Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/vpUIss1hks
Novartis Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/vpUIss1hks
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
#NEJM Dans le cadre du traitement du lymphome diffus à grandes cellules B, le #tisagenlecleucel a produit des réponses durables chez les patients sous thérapie cellulaire CAR T.
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
RT @NEJM: Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://…
Original Article: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://t.co/4uzijXERsX https://t.co/tYGEFkfL9S
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @SaudiLeukemia: #CART cell in Non Hodgkin Lymphoma : KYMRIAH for DLBCL : The best overall response rate was 52% (95% confidence interval…
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/F8QewxYk8B
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @HemeHillis: The heme program @HamHealthSci participated in this - great to see Ronan Foley on the author list. Really takes treatment t…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @SaudiLeukemia: #CART cell in Non Hodgkin Lymphoma : KYMRIAH for DLBCL : The best overall response rate was 52% (95% confidence interval…
#CART cell in Non Hodgkin Lymphoma : KYMRIAH for DLBCL : The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% | NEJM https://t.co/2bjojXIYXU
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
CAR-T-celle (altså genetisk modificerede immuncelle) behandling af svært behandlelig lymfeknudekræft.
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
Follow up of only 14 month is difficult to say durable response.
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
Car T-cell: Time has come. #JulietTrial #CarTCellTherapy #CarT #NEJM Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/munaMGXmoa
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @HemeHillis: The heme program @HamHealthSci participated in this - great to see Ronan Foley on the author list. Really takes treatment t…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @HemeHillis: The heme program @HamHealthSci participated in this - great to see Ronan Foley on the author list. Really takes treatment t…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
The heme program @HamHealthSci participated in this - great to see Ronan Foley on the author list. Really takes treatment to the next level, huge un-met need. #myHHS
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…